(BASU; SHAH; BROWN JR., 2015BASU, P. P.; SHAH, N. J.; BROWN, J. R. R. Simeprevir and sofosbuvir with modified doses of ribavirin (RBV) therapy on telaprevir experienced co infected (with HIV) cirrhotics with chronic hepatitis C (CHC). A randomized open label clinical pilot study: Stop C. Journal of Hepatology, Copehnagen, v. 62, p. S643, 2015. Disponível em: <http://www.journal-of-hepatology.eu/article/S0168-8278(15)31022-9/abstract>. Acesso em: 2 maio 2016. http://www.journal-of-hepatology.eu/arti...
) |
Stop C |
1 |
SOF+SMV+RBV |
24 e 16 |
NR |
50 |
NR |
NR |
1 (100%) |
100 |
NR |
(LUETKEMEYER ET AL., 2016LUETKEMEYER, A. F. et al. 12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Clinical Infectious Diseases, Chicago, v. 62, n. 12, p. 1489-1496, 2016. Disponível em: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885650/>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pmc/article...
) |
ALLY-2 |
2 |
DCV+SOF |
16 |
EUA |
151 |
88,7 |
53 |
1 (84%), 2 (8%), 3 (6%) e 4 (2%) |
15,2 |
34 |
(MOLINA ET AL., 2015MOLINA, J. M. et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. The Lancet, Londres, v. 385, n. 9973, p. 1098-106, fev. 2015. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/25659285>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pubmed/2565...
) |
PHOTON-2 |
1 |
SOF+RBV |
24 ou 12 |
>2 países |
274 |
80,6 |
49,6 |
1 (40%), 2 (9%), 3 (38%) e 4 (11%) |
19,7 |
20 |
(NAGGIE ET AL., 2015NAGGIE, S. et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal Of Medicine, Massachusetts, v. 373, n. 8, p. 705-13, 2015.) |
ION-4 |
1 |
LED+SOF |
12 |
EUA e Porto Rico |
335 |
82 |
52 |
1 (98%) e 4 (2%) |
20 |
55 |
(OSINUSI ET AL., 2015OSINUSI, A. et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Journal of the American Medical Association, Chigado, v. 313, n. 12, p. 1232-1239, 2015. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/25706232>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pubmed/2570...
) |
NR |
1 |
LED+SOF |
12 |
EUA |
50 |
74 |
58,2 |
1 (100%) |
0 |
0 |
(ROCKSTROH ET AL., 2015ROCKSTROH, J. K. et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The Lancet HIV, Amsterdam, v. 2, n. 8, p. 319-327, 2015. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/26423374>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pubmed/2642...
) |
C-EDGE CO-INFECTION |
1 |
GRA+ELB |
12 |
>2 países |
218 |
84 |
48,7 |
1 (86%), 4 (13%) e 6 (1%) |
16 |
0 |
(SULKOWSKI ET AL., 2014SULKOWSKI, M. S. et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Journal of the American Medical Association, Chicago, v. 312, n. 4, p. 353-361, 2014. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/25706092>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pubmed/2570...
) |
NR |
1 |
SOF+RBV |
12 ou 24 |
EUA e Porto Rico |
223 |
83 |
50,3 |
1 (51%), 2 (30%) e 3 (20%) |
10 |
18,3 |
(SULKOWSKI, M. ET AL., 2015ASULKOWSKI, M. S. et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. The Lancet, Londres, v. 385, n. 9973, p. 1087-1097, 2015a. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/25467560>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pubmed/2546...
) |
C-WORTHY |
3 |
GRA+ELB±RBV |
12 |
>2 países |
59 |
79,6 |
46,2 |
1 (100%) |
0 |
0 |
(SULKOWSKI, M. S. ET AL., 2015BSULKOWSKI, M. S. et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Journal of the American Medical Association, Chicago, v. 313, n. 12, p. 1223-1231, 2015b. Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/25706092>. Acesso em: 20 maio 2016. https://www.ncbi.nlm.nih.gov/pubmed/2570...
) |
Turquoise-I |
3 |
PrOD+RBV |
12 ou 24 |
EUA e Porto Rico |
63 |
92 |
50,9 |
1 (100%) |
19 |
33 |
(WYLES ET AL., 2015WYLES, D. L. et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. New England Journal Of Medicine, Massachusetts, v. 373, n. 8, p. 714-25, 2015.) |
ALLY-2 |
2 |
DCV+SOF |
8 ou 12 |
EUA |
203 |
87,1 |
53,3 |
1 (83%), 2 (9%), 3 (6%) e 4 (1%) |
14 |
26 |